- Canntab Therapeutics Limited (PILL) has completed its second delivery of two additional SKUs ordered by MediPharm Labs Corp
- It has now fulfilled 80 percent of the purchase amount contracted under the wholesale tablet purchase agreement
- The total purchase order was approximately C$1.3 million
- Canntab is a Canadian biopharmaceutical company focused on the manufacturing and distribution of a suite of hard pill cannabinoid formulations
- Canntab Therapeutics (PILL) is up 3.16 percent and is trading at C$0.98 at 2:15 pm EST
Canntab Therapeutics Limited (PILL) has completed its second delivery of two additional SKUs ordered by MediPharm Labs Corp.
This delivery includes 12.5mg CBD caplets (hard tablets in the shape of capsules) and 25mg CBD caplets for approximately C$550,000.
Canntab has now fulfilled 80 percent of the purchase amount contracted under the wholesale tablet purchase agreement entered into by Canntab and MediPharm Labs in June 2020.
Further to Canntab’s previous announcement on December 1, 2020, the total purchase order was approximately C$1.3 million.
The first delivery included 2.5mg THC and 5mg THC tablets.
The final shipment, which is currently in production and anticipated to be completed by month-end is for a combination caplet that contains 25mg CBD and 5mg THC.
“Not only will this shipment reflect our second consecutive quarter of revenue. It also reflects our ability to ramp up our production by now having successfully produced and delivered 4 unique SKU’s including 2.5mg THC, 5mg THC, 12.5mg CBD and 25mg CBD hard oral dose tablets and caplets,” stated Larry, Latowsky, Chief Executive Officer, Canntab Therapeutics.
“With our production capabilities now ramping, our focus will now be on expanding our sales channels by marketing directly to consumers and the health care community within Canada,” added Latowsky.
Canntab is currently evaluating several partnering opportunities in Canada, the United States and Europe. It will provide details of these efforts to its shareholders as soon as they become material.
It has also filed more than a dozen patent applications in the United States and Canada and other jurisdictions for which two have now been granted or allowed.
Canntab is a Canadian biopharmaceutical company focused on manufacturing and distributing a suite of hard pill cannabinoid formulations in multiple doses and timed-release combinations.
Canntab Therapeutics (PILL) is up 3.16 percent and is trading at C$0.98 at 2:15 pm EST.
